Inpatient and Outpatient Orderable

OnkoSight Myeloid Seq Build info

Synonyms

  • ONKOSIGHT NGS MYELOID MALIGNANCIES
  • ONKOMYELO
  • LAB10522

Procedure Name

ONKOSIGHT NGS MYELOID MALIGNANCIES

Procedure Master Number

LAB10522

Procedure ID

111548

Clinical Info

This test is used to aid diagnosis, prognostic risk assessment and therapeutic selection in various myeloid and lymphoid malignancies.
This test includes the following genes: ABL1, ANKRD26, ARID1A, ASXL1, ATM, ATRX, B2M, BCL2, BCL6, BCOR, BCORL1, BIRC3, BRAF, BRCC3, BTK, CALR, CARD11, CBL, CBLB, CBLC, CCND1, CCND3, CD274, CD79A, CD79B, CDK4, CDKN1B, CDKN2A, CDKN2B, CEBPA, CIITA, CREBBP, CRLF2, CSF1R, CSF3R, CSNK1A1, CTCF, CUX1, CXCR4, DDX41, DKC1, DNMT3A, EBF1, ELANE, EP300, ERG, ETNK1, ETV6, EZH2, FAS, FBXW7, FGFR1, FGFR3, FLT3, FOXO1, GATA1, GATA2, GNA13, GNAS, GNB1, HRAS, IDH1, IDH2, IKZF1, IKZF3, IL7R, IRF4, JAK1, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, MALT1, MAP2K1, MAPK1, MED12, MEF2B, MPL, MYC, MYD88, NF1, NFE2, NOTCH1, NOTCH2, NPM1, NRAS, NSD2, NT5C2, P2RY8, PAX5, PDCD1, PDGFRA, PHF6, PIGA, PIK3CA, PIK3CD, PIK3CG, PIK3R1, PIM1, PLCG2, PML, POT1, PPM1D, PRDM1, PRPF8, PTEN, PTPN11, RAD21, RB1, RHOA, RIT1, RUNX1, SAMD9, SAMD9L, SBDS, SETBP1, SETD2, SF3B1, SH2B3, SMC1A, SMC3, SOCS1, SRSF2, STAG2, STAT3, STAT5B, STAT6, TCF3, TERC, TERT, TET2, TNFAIP3, TNFRSF14, TP53, U2AF1, WT1, UBA1, XPO1 and ZRSR2.

Specimen Sources

 Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous Bone Marrow Bone Marrow Aspirate

Specimen Types

 Aspirate Blood Bone Marrow

Container

Specimen:
Whole blood, bone marrow, cell pellets from whole blood or cell suspension
Container:
Lavender-top (EDTA) tube; green-top (sodium heparin) tube; cells left over from flow cytometry analysis,
either fresh cell suspension or fresh/frozen cell pellet spun down from suspension.
Cell suspension should be shipped on ice.

Collection Instructions


Causes for Rejection
Specimen does not meet criteria for sample type, container, minimum volume, collection and storage; frozen whole blood or marrow; 
leaking tube; clotted blood or marrow; grossly hemolyzed specimen or otherwise visibly degraded; contaminated specimen; 
contains suspicious foreign material

Specimen Volume

Volume
3-5 mL (blood), 1-2 mL (bone marrow)
Minimum Volume
3 mL (blood), 1 mL (bone marrow)

Transport Instructions

Room Temperature

Specimen Stability

Methodology

Pan-Heme NGS assay utilizes capture-based next-generation sequencing of whole genomic DNA libraries to identify gene alterations
that have diagnostic, prognostic and therapeutic significance in hematologic malignancies.

Days Performed

TAT: 10 - 14 Days

Performing Laboratory

Labcorp

CPT

81450

PDM

 1659893

Only Orderable at Locations:

 Orderable Everywhere

Results
Component Name Base Name Common Name External Name
ONKOSIGHT MYELOID SEQUENCE ONKOMYSEQ ONKO MYELO SEQ Onkosight Myeloid Sequence
MYE THERAPEUTIC AND PROGNOSTIC ASSOCIATIONS MYEPROG MYE THERAPEUTIC AND PROGNOSTIC ASSOCIATIONS Mye Therapeutic And Prognostic Associations
MYE INTERPRETATION SUMMARY MYEINTERP MYE INTERPRETATION SUMMARY Mye Interpretation Summary
MYE DETAILED GENETIC INTERPRETATION 1 MYEGENINT1 MYE DETAILED GENETIC INTERPRETATION 1 Mye Detailed Genetic Interpretation 1
MYE DETAILED GENETIC INTERPRETATION 2 MYEGENINT2 MYE DETAILED GENETIC INTERPRETATION 2 Mye Detailed Genetic Interpretation 2
MYE CLINICAL TRIALS 1 MYECT1 MYE CLINICAL TRIALS 1 Mye Clinical Trials 1
MYE CLINICAL TRIALS 2 MYECT2 MYE CLINICAL TRIALS 2 Mye Clinical Trials 2
MYE TECHNICAL SUMMARY MYETECH MYE TECHNICAL SUMMARY Mye Technical Summary
MYE METHODS MYEMETHOD MYE METHODS Mye Methods
MYE REFERENCES 1 MYEREF1 MYE REFERENCES 1 Mye References 1
MYE REFERENCES 2 MYEREF2 MYE REFERENCES 2 Mye References 2
MYE REPORT FOOTER MYEREPORT MYE REPORT FOOTER Mye Report Footer
MYE ADDENDUM MYE MYE ADDENDUM Mye Addendum
MYE ALLELE FREQUENCIES MYE MYE ALLELE FREQUENCIES Mye Allele Frequencies

Result Interpretation

See Report

 

Forms
edit